HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 4 (2007), Issue 12 (December)

1. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation.
   Virology, 370(1): 113-21. [Abstract] [Full-text]
2. Novel (n)PKC kinases phosphorylate Nef for increased HIV transcription, replication and perinuclear targeting.
   Virology, 370(1): 45-54. [Abstract] [Full-text]
3. Neutralizing antibodies decrease the envelope fluidity of HIV-1.
   Virology, 370(1): 142-50. [Abstract] [Full-text]
4. Relative concordance of human immunodeficiency virus oligomeric and monomeric envelope in CCR5 coreceptor usage.
   Virology, 370(2): 443-50. [Abstract] [Full-text]
5. Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4+ T lymphocytes.
   Virology, 370(2): 382-91. [Abstract] [Full-text]
6. Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells.
   Virology, 370(2): 246-54. [Abstract] [Full-text]
7. Adaptation of the human immunodeficiency virus type 1 envelope glycoproteins to new world monkey receptors.
   J Virol, 82(1): 346-57. [Abstract] [Full-text]
8. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration.
   J Virol, 82(1): 538-45. [Abstract] [Full-text]
9. Different abilities of escape mutant-specific cytotoxic T cells to suppress replication of escape mutant and wild-type human immunodeficiency virus type 1 in new hosts.
   J Virol, 82(1): 138-47. [Abstract] [Full-text]
10. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice.
    J Virol, 82(1): 207-19. [Abstract] [Full-text]
11. Quantitation of HLA proteins incorporated by human immunodeficiency virus type 1 and assessment of neutralizing activity of anti-HLA antibodies.
    J Virol, 82(1): 428-34. [Abstract] [Full-text]
12. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.
    J Virol, 82(1): 115-25. [Abstract] [Full-text]
13. WFDC1/ps20 is a novel innate immunomodulatory signature protein of human immunodeficiency virus (HIV)-permissive CD4+ CD45RO+ memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infection.
    J Virol, 82(1): 471-86. [Abstract] [Full-text]
14. Novel cytotoxic T-lymphocyte escape mutation by a three-amino-acid insertion in the human immunodeficiency virus type 1 p6Pol and p6Gag late domain associated with drug resistance.
    J Virol, 82(1): 495-502. [Abstract] [Full-text]
15. Chronology of the HIV-1 CRF07_BC expansion in East Asia.
    AIDS, 22(1): 156-8. [Abstract] [Full-text]
16. Short-term increase in unsafe sexual behaviour after initiation of HAART in Côte d'Ivoire.
    AIDS, 22(1): 154-6. [Abstract] [Full-text]
17. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
    AIDS, 22(1): 152-4. [Abstract] [Full-text]
18. First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants.
    AIDS, 22(1): 149-51. [Abstract] [Full-text]
19. High HIV incidence in a community with high HIV prevalence in rural South Africa: findings from a prospective population-based study.
    AIDS, 22(1): 139-44. [Abstract] [Full-text]
20. Reduced rates of HIV acquisition during unprotected sex by Kenyan female sex workers predating population declines in HIV prevalence.
    AIDS, 22(1): 131-7. [Abstract] [Full-text]
21. 'Time is costly': modelling the macroeconomic impact of scaling-up antiretroviral treatment in sub-Saharan Africa.
    AIDS, 22(1): 107-13. [Abstract] [Full-text]
22. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis.
    AIDS, 22(1): 97-105. [Abstract] [Full-text]
23. Survival following HIV infection of a cohort followed up from seroconversion in the UK.
    AIDS, 22(1): 89-95. [Abstract] [Full-text]
24. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance.
    AIDS, 22(1): 75-82. [Abstract] [Full-text]
25. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.
    AIDS, 22(1): 67-74. [Abstract] [Full-text]
26. HIV-1-infected CD8+CD4+ T cells decay in vivo at a similar rate to infected CD4 T cells during HAART.
    AIDS, 22(1): 57-65. [Abstract] [Full-text]
27. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study.
    AIDS, 22(1): 47-56. [Abstract] [Full-text]
28. IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages.
    AIDS, 22(1): 39-45. [Abstract] [Full-text]
29. An unanticipated lack of consensus cytotoxic T lymphocyte epitopes in HIV-1 databases: the contribution of prediction programs.
    AIDS, 22(1): 33-7. [Abstract] [Full-text]
30. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.
    AIDS, 22(1): 23-31. [Abstract] [Full-text]
31. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    AIDS, 22(1): 15-21. [Abstract] [Full-text]
32. Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment.
    Bioinformatics, 24(1): 34-41. [Abstract] [Full-text]
33. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
    AIDS, 22(2): 311-3. [Abstract] [Full-text]
34. Combination antiretroviral therapy failure and HIV super-infection.
    AIDS, 22(2): 309-11. [Abstract] [Full-text]
35. HIV dynamics and immunosenescence.
    AIDS, 22(2): 307-9. [Abstract] [Full-text]
36. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort.
    AIDS, 22(2): 289-99. [Abstract] [Full-text]
37. Population prevalence of reported and unreported HIV and related behaviors among the household adult population in New York City, 2004.
    AIDS, 22(2): 281-7. [Abstract] [Full-text]
38. Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection.
    AIDS, 22(2): 275-9. [Abstract] [Full-text]
39. Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome?
    AIDS, 22(2): 269-73. [Abstract] [Full-text]
40. Asymptomatic myocardial ischaemia in HIV-infected adults.
    AIDS, 22(2): 257-67. [Abstract] [Full-text]
41. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.
    AIDS, 22(2): 249-55. [Abstract] [Full-text]
42. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl.
    AIDS, 22(2): 237-47. [Abstract] [Full-text]
43. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
    AIDS, 22(2): 227-36. [Abstract] [Full-text]
44. NKG2C is a major triggering receptor involved in the V[delta]1 T cell-mediated cytotoxicity against HIV-infected CD4 T cells.
    AIDS, 22(2): 217-26. [Abstract] [Full-text]
45. Differences in proviral DNA load between HIV-1- and HIV-2-infected patients.
    AIDS, 22(2): 211-5. [Abstract] [Full-text]
46. Maternal Herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: results of a case control study.
    AIDS, 22(2): 193-201. [Abstract] [Full-text]
47. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
    AIDS, 22(2): F1-9. [Abstract] [Full-text]
48. Immune factors involved in the cervical immune response in the HIV/HPV co-infection.
    J Clin Pathol, 61(1): 84-8. [Abstract] [Full-text]
49. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation.
    Biochem Biophys Res Commun, 366(1): 29-35. [Abstract] [Full-text]
50. Characterization of a chemokine receptor CCR5-negative T cell line and its use in determining human immunodeficiency virus type 1 phenotype.
    J Med Virol, 80(2): 192-200. [Abstract] [Full-text]
51. HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy.
    J Med Virol, 80(2): 201-8. [Abstract] [Full-text]
52. Molecular epidemiology of HIV-1 subtypes and drug resistant strains in Taiwan.
    J Med Virol, 80(2): 183-91. [Abstract] [Full-text]
53. Envelope lipids regulate the in vitro assembly of the HIV-1 capsid.
    Biophys J, 94(2): L8-10. [Abstract] [Full-text]
54. Early diagnosis of human immunodeficiency virus in infants using polymerase chain reaction on dried blood spots in Botswana's national program for prevention of mother-to-child transmission.
    Pediatr Infect Dis J, 27(1): 22-6. [Abstract] [Full-text]
55. Resolution of de novo HIV production and trafficking in immature dendritic cells.
    Nat Methods, 5(1): 75-85. [Abstract] [Full-text]

© 2004-2010 HIV Research Today. All Rights Reserved.